top of page
Pipeline_NP top bg.png
Pipeline_NP top bg.png
Pipeline
MVR-V001

Application

COVID-19 Therapeutics
Pipeline Overview

Angiotensin-converting enzyme 2(ACE2) has been identified as a cellular receptor for the entry of COVID-19. There are many studies on the development of coronavirus inhibitors, using the water-soluble site of ACE2. MVRIX developed nanodisc attached with ACE2 protein, confirmed effectiveness on both pathways of coronavirus entry. Compared to soluble ACE2, MVR-V001 showed much superior antiviral efficacy.

Higher survival rate of MVR-V001
Prophylactyic, IN
cov-01.png
cov-02.png
cov-06.png

In vivo experiments confirmed that MVR-V001 has a better effect than sACE2-Fc in virus prevention and treatment

Therapeutic, IV
cov-04.png
cov-05.png
cov-06.png
Therapeutic effect against COVID-19 mutations
var-01.png
var-02.png
var-03.png
var-0.png
var-04.png
var-05.png
var-06.png
var-07.png

Efficacy confirmed to all COVID-19 virus variants known, including Omicron BA.5 -> Applicable immediately to newly emerging COVID-19 variants.

bottom of page